SIEHT is a healthcare provider specializing in eye care services, including cataract surgery, LASIK vision correction, glaucoma treatment, and general eye exams.

SIEHT

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Adaptilens is developing an accommodating intraocular lens (IOL) that adapts to the patient's surroundings, aiming to replicate the human lens as closely as possible.

Adaptilens

Azura Ophthalmics focuses on the development of ophthalmic keratolytics for the treatment of ocular conditions.

Metric
Company Name	SIEHT	AbbVie Inc.	Adaptilens	Azura Ophthalmics
Symbol		ABBV
MSH ID	COM:SIEHT	COM:ABBVIE	COM:ADAPTILENS	COM:AZURAOPHTHALMICS
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Optometry	Drug Manufacturers - General	Medical Devices	Biopharmaceuticals
Country	US	US	US	US
Stage				Grant
Employee Count		50K	7
Website	sieht.com	abbvie.com	adaptilens.com	azuraophthalmics.com
LinkedIn			adaptilens
Founders

Metric
Market Cap		296.91B
Enterprise Value
Monthly Web Traffic	419	1.18M
Web Traffic Growth	-0.85	0.51
Valuation
Raised Capital		15B

Metric
Revenue		54.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit		45.54B
EBITDA		18.10B
Operating Income		17.43B
Net Income		4.86B
EPS		2.75
Diluted EPS		2.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.72
Operating Profit Margin		0.27
EBITDA Margin		0.33
Net Profit Margin		0.11
Return on Equity		0.57
Return on Assets		0.04
Return on Capital Employed		0.15

COM:SIEHT

SIEHT

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		46.58
P/B Ratio		25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.36
EV Multiple		17.44

Metric
Days Sales Outstanding		75.54
Days Payables Outstanding
Days Inventory Outstanding		102.41
Operating Cycle		181.71
Cash Conversion Cycle		179.57
Asset Turnover		0.40

Metric
Operating Cash Flow		22.84B
Free Cash Flow		22.06B
Cash Flow to Debt		0.38
Operating Cash Flow/Sales		0.42
Free Cash Flow Yield		0.08

Metric
Cash & Equivalents		12.81B
Accounts Receivable		66M
Inventory		4.10B
Goodwill		32.29B
Debt to Capitalization		0.91
Debt to Assets		0.45
Current Ratio		0.96
Quick Ratio		0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.14
SG&A to Revenue